HC Wainwright Increases FY2026 Earnings Estimate for Corcept Therapeutics

On October 31st, HC Wainwright, a respected research firm, announced an increase in its earnings per share (EPS) estimate for Corcept Therapeutics Incorporated (NASDAQ:CORT). According to analyst S. Ramakanth, the new projected EPS for the fiscal year 2026 is $3.67, which is an increase from the previous estimate of $3.55. This upgrade reflects the firm's optimism about the company's future earnings potential.

Current Stock Rating and Price Target

HC Wainwright currently holds a "Buy" rating on Corcept Therapeutics, alongside a price target of $80.00 per share. In comparison, the consensus estimate for the company’s earnings in the current fiscal year stands at $1.12 per share. Additionally, HC Wainwright provided forecasts for future fiscal years, estimating earnings of $4.78 per share in 2027 and $5.64 per share in 2028.

Other Analysts' Ratings

Several other analysts have also weighed in on Corcept Therapeutics. For instance, Sandler O’Neill reiterated a "buy" rating on October 18th. Meanwhile, Truist Financial revised its price objective for the stock to $76.00 from $65.00 and maintained a "buy" rating. StockNews.com has upgraded Corcept shares from a "buy" to a "strong-buy" rating. Additionally, Canaccord Genuity set a price target of $38.00 for the stock, and Piper Sandler raised its price target from $38.00 to $67.00, labeling it as "overweight." Overall, five analysts have rated Corcept Therapeutics with a "buy" rating, and one has given it a "strong buy," indicating positive sentiment towards the stock.

Recent Stock Performance

As of November 3rd, Corcept Therapeutics shares opened at $47.62. The company has experienced significant stock movements, with a 50-day moving average of $42.40 and a 200-day average of $34.57. Corcept Therapeutics boasts a market capitalization of $4.98 billion, a price-to-earnings ratio of 37.79, and a beta of 0.46. In the past year, the stock has fluctuated between a low of $20.84 and a high of $50.07.

Recent Earnings Report

Corcept Therapeutics recently reported its quarterly earnings on October 30th. For this quarter, the firm reported earnings of $0.41 per share, surpassing analyst expectations of $0.27 by $0.14. The company's revenue for the quarter was $182.55 million, exceeding the consensus estimate of $171.97 million. This marks a 47.7% increase in revenue compared to the same quarter last year, illustrating strong growth. The net margin was 22.35%, and the return on equity was 25.53%.

Institutional Trading Activity

Recent trading activity indicates a robust interest in Corcept Therapeutics from institutional investors. The firm saw several large purchases in the last quarter, including stakes valued at approximately $25,000 to $36,000 made by various firms. Notably, hedge funds and institutional investors now own 93.61% of the company's shares.

Insider Transactions

In terms of insider transactions, CEO Gary Charles Robb sold 11,000 shares on October 1st at an average price of $46.28, totaling approximately $509,080. Following this sale, he still retains 22,772 shares, valued at roughly $1,053,888. Another insider, William Guyer, sold 10,000 shares on September 3rd for about $353,000, maintaining a position of 6,039 shares. Overall, insiders have sold 24,101 shares valued at about $972,817 over the past 90 days, while insiders still hold 20.50% of the company's stock.

About Corcept Therapeutics

Corcept Therapeutics focuses on discovering and developing medications for severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. One of its key products, Korlym, is prescribed for treating hyperglycemia associated with hypercortisolism in adults with endogenous Cushing's syndrome, particularly those with type 2 diabetes or glucose intolerance.

Corcept, Earnings, Stock